A phase II study of Xcellerated T cells™ in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL)
John G. Gribben(Queen Mary University of London), Mark W. Frohlich, Ronald Berenson(University of Freiburg), Nancy L. Bartlett(Washington University in St. Louis), Charles H. Redfern(Sharp Memorial Hospital), Joe Stephenson(Neurology Centers of the Carolinas), V. M. Mizuno, Ralph V. Boccia(Center for Cancer and Blood Disorders), Michael S. Milder
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k